Alphabet (the umbrella corp that owns Google and DeepMind) just launched Isomorphic Labs (IL). According to the new company’s blog, it’s “reimagining the entire drug discovery process from first principles with an AI-first approach.” In other words: The CEO of DeepMind, Demis Hassabis, is going to run a drug-discovery spinoff. Up front: This seems like a really good thing. DeepMind’s AlphaFold 2 has supposedly revolutionized how researchers study protein structures. And Hassabis is obviously pretty good at running a lab. But let’s just have a gander at the company’s blog, shall we? Here’s an interesting quote: At its most fundamental…
This story continues at The Next Web
Or just read more coverage about: Google